Zhejiang Orient Gene Biotech Co., Ltd (SHA:688298)
China flag China · Delayed Price · Currency is CNY
18.95
+0.04 (0.21%)
Sep 4, 2026, 3:00 PM CST

SHA:688298 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
991.65930.56811.28812.348,74110,152
Other Revenue
16.8216.8216.647.8127.2316.98
1,008947.38827.92820.168,76810,169
Revenue Growth
24.08%14.43%0.95%-90.65%-13.78%211.43%
Cost of Revenue
596.88586.63659.26640.515,1582,682
Gross Profit
411.58360.75168.66179.643,6107,487
Selling, General & Admin
604.61593.3597.01534.55755.811,133
Research & Development
197.28230.81290.49260.86511.56428.52
Other Operating Expenses
17.8516.4714.4614.2289.1672.75
Operating Expenses
824.19845.03932.06839.81,3501,667
Operating Income
-412.61-484.27-763.4-660.152,2605,820
Interest Expense
-9.91-9.91-19.25-18.12-6.97-0.94
Interest & Investment Income
97.4689.03222.78249.68122.8746.02
Currency Exchange Gain (Loss)
-5.07-5.0744.9187.17495.21-99.72
Other Non Operating Income (Expenses)
-112.06-5.75-0.361.5-2.44-2.09
EBT Excluding Unusual Items
-442.19-415.97-515.32-339.922,8695,763
Impairment of Goodwill
---55.58-57.31-15.41-
Gain (Loss) on Sale of Investments
-5.34-1.610.65-8.991.660.04
Gain (Loss) on Sale of Assets
1.061.680.82-0.64-0.13-0.04
Asset Writedown
-173.27-173.64-26-6.09-351.04-
Other Unusual Items
6.036.030.128.72-33.166.71
Pretax Income
-613.71-583.49-585.31-404.232,4715,770
Income Tax Expense
41.6913.91-16.4914.04373.32829.32
Earnings From Continuing Operations
-655.41-597.41-568.82-418.272,0974,941
Minority Interest in Earnings
22.6823.8139.820.69-29.72-20.46
Net Income
-632.73-573.6-529.02-397.582,0684,920
Net Income to Common
-632.73-573.6-529.02-397.582,0684,920
Net Income Growth
-----57.98%193.33%
Shares Outstanding (Basic)
191192197202202202
Shares Outstanding (Diluted)
191192197202202202
Shares Change
-1.45%-2.13%-2.56%0.13%-0.02%2.16%
EPS (Basic)
-3.31-2.98-2.69-1.9710.2624.40
EPS (Diluted)
-3.31-2.98-2.69-1.9710.2624.40
EPS Growth
-----57.97%187.12%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-401.11-501.57-1,272-2,6421,9444,696
Free Cash Flow Per Share
-2.10-2.61-6.47-13.099.6423.29
Dividend Per Share
----1.6673.679
Dividend Growth
-----54.69%47.14%
Gross Margin
40.81%38.08%20.37%21.90%41.18%73.63%
Operating Margin
-40.91%-51.12%-92.21%-80.49%25.78%57.23%
Profit Margin
-62.74%-60.55%-63.90%-48.48%23.58%48.38%
Free Cash Flow Margin
-39.77%-52.94%-153.69%-322.09%22.17%46.18%
EBITDA
-238.82-306.84-582.06-508.832,3385,849
EBITDA Margin
-23.68%-32.39%-70.30%-62.04%26.66%57.52%
D&A For EBITDA
173.78177.43181.34151.3377.8428.77
EBIT
-412.61-484.27-763.4-660.152,2605,820
EBIT Margin
-40.91%-51.12%-92.21%-80.49%25.78%57.23%
Effective Tax Rate
----15.11%14.37%
Revenue as Reported
947.38947.38827.92820.168,76810,169
Advertising Expenses
-24.6922.1424.5213.47-